<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530630</url>
  </required_header>
  <id_info>
    <org_study_id>20-01021384</org_study_id>
    <nct_id>NCT04530630</nct_id>
  </id_info>
  <brief_title>Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant</brief_title>
  <official_title>The Efficacy, Safety, and Tolerability of Switching to a Bictegravir (BIC)/Emtricitabine(FTC)/Tenofovir Alafenamide (TAF) Regimen in Virally Suppressed HIV-Positive Patients Post-Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study, where participants will be switched from their current HIV&#xD;
      medication to the study drug, Biktarvy. Open-label means both the investigator and the&#xD;
      participant will know what drug will be given. Participants will be followed for 48 weeks in&#xD;
      order to monitor the efficacy, safety and tolerability of Biktarvy. The investigator&#xD;
      hypothesizes that Biktarvy will be an important addition to the management of HIV-positive&#xD;
      post renal transplant patients, especially since it is a one pill daily dosing regimen,&#xD;
      thereby decreasing the pill burden in this population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with plasma HIV-1 RNA &lt;50 copies/ml</measure>
    <time_frame>Week 48</time_frame>
    <description>HIV viral loads will be obtained from lab reports</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by number of participants with at least one adverse event</measure>
    <time_frame>Approximately 1 month after final study visit</time_frame>
    <description>Adverse events will only include those that are determined to be related to the study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in tolerated dose of Biktarvy in HIV positive post renal transplant participants as measured by HIV Treatment Satisfaction Questionnaire</measure>
    <time_frame>Week 4, Week 12, Week 24, Week 36, Week 48, 3 Month Follow Up, 6 Month Follow Up</time_frame>
    <description>Tolerability will be measured by the health-related quality of life questionnaire to assess satisfaction with a one pill regimen. The health-related questionnaire ranges from 0 to 6 with higher scores indicating greater satisfaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in interaction between plasma concentrations for Bictegravir/Emtricitabine/Tenofovir alafenamide, intracellular TAF levels, tacrolimus levels, and renal function</measure>
    <time_frame>Day 1, Day 3, Day 5, Day 8, Day 11, Day 22, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48 (End of study), 3 Month Follow Up, 6 Month Follow Up</time_frame>
    <description>Relationships will be determined by linear regression analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T lymphocyte cell count/percentages post renal transplant</measure>
    <time_frame>Day 1, Week 4, Week 12, Week 24, Week 36, Week 48 (End of study), 3 Month Follow Up, 6 Month Follow Up</time_frame>
    <description>CD4 lymphocyte counts and percentages will be obtained from lab reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between rejection rates of the kidney transplant post renal and Tacrolimus levels</measure>
    <time_frame>Approximately 3 months after primary outcome completion</time_frame>
    <description>Data for kidney graft rejection rates will be extracted from biopsy confirmed rejections and observed along with levels of Tacrolimus obtained from blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participants satisfaction with reduced pill burden, as measured by the health-related quality of life questionnaire</measure>
    <time_frame>Week 4, Week 12, Week 24, Week 36, Week 48 (End of study), 3 Month Follow Up, 6 Month Follow Up</time_frame>
    <description>Satisfaction will be measured by the self-reporting health-related quality of life questionnaire ranging from 0 to 6 with higher scores indicating greater satisfaction with Biktarvy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HIV Infections</condition>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Biktarvy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a Biktarvy tablet orally once daily with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIKTARVY 50Mg-200Mg-25Mg Tablet</intervention_name>
    <description>A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.</description>
    <arm_group_label>Biktarvy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years old on day of signing informed consent&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Received a previous renal transplant&#xD;
&#xD;
          -  Must have controlled HIV infection for at least 3 months prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received a kidney from a donor who was HIV positive (unless a false positive)&#xD;
&#xD;
          -  Currently taking Biktarvy for treatment of HIV&#xD;
&#xD;
          -  Has allergies to any of the HIV medications in Biktarvy (bictegravir, emtricitabine,&#xD;
             or tenofovir alafenamide)&#xD;
&#xD;
          -  Currently taking dofetilide or rifampin&#xD;
&#xD;
          -  Is pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine B Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Gwak, BA</last_name>
    <phone>212-746-4089</phone>
    <email>ang4021@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth L Salsgiver, MPH</last_name>
    <phone>212-746-4089</phone>
    <email>els7021@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Gwak, BA</last_name>
      <phone>212-746-4089</phone>
      <email>ang4021@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth L Salsgiver, MPH</last_name>
      <phone>2127464089</phone>
      <email>els7021@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine B Small, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18. Erratum in: Lancet HIV. 2018 Jun 22;:.</citation>
    <PMID>29925489</PMID>
  </reference>
  <reference>
    <citation>Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.</citation>
    <PMID>28867497</PMID>
  </reference>
  <reference>
    <citation>Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.</citation>
    <PMID>28219610</PMID>
  </reference>
  <reference>
    <citation>Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6.</citation>
    <PMID>28993180</PMID>
  </reference>
  <reference>
    <citation>Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):530-7. doi: 10.1097/QAI.0000000000000908.</citation>
    <PMID>26627107</PMID>
  </reference>
  <reference>
    <citation>Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs. 2018 Nov;78(17):1817-1828. doi: 10.1007/s40265-018-1010-7. Review. Erratum in: Drugs. 2019 Mar 22;:.</citation>
    <PMID>30460547</PMID>
  </reference>
  <reference>
    <citation>Eron JJ, Lelievre J-D, Kalayjian R, Slim J, et al. Safety and Efficacy of E/C/F/TAF in HIV-Infected Adults on Chronic Hemodialysis (Abstract, poster 732 presented at CROI 2018).</citation>
  </reference>
  <reference>
    <citation>Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18;363(21):2004-14. doi: 10.1056/NEJMoa1001197. Erratum in: N Engl J Med. 2011 Mar 17;364(11):1082.</citation>
    <PMID>21083386</PMID>
  </reference>
  <reference>
    <citation>Locke JE, Mehta S, Reed RD, MacLennan P, Massie A, Nellore A, Durand C, Segev DL. A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients. J Am Soc Nephrol. 2015 Sep;26(9):2222-9. doi: 10.1681/ASN.2014070726. Epub 2015 Mar 19.</citation>
    <PMID>25791727</PMID>
  </reference>
  <reference>
    <citation>Gunawardana M, Remedios-Chan M, Miller CS, Fanter R, Yang F, Marzinke MA, Hendrix CW, Beliveau M, Moss JA, Smith TJ, Baum MM. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother. 2015 Jul;59(7):3913-9. doi: 10.1128/AAC.00656-15. Epub 2015 Apr 20.</citation>
    <PMID>25896688</PMID>
  </reference>
  <reference>
    <citation>Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS. 2017 Mar 27;31(6):765-770. doi: 10.1097/QAD.0000000000001405.</citation>
    <PMID>28099191</PMID>
  </reference>
  <reference>
    <citation>Pharmacoeconomic Review Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) (Biktarvy): (Gilead Sciences Canada, Inc.): Indication: A complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance the individual components of Biktarvy [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK539546/</citation>
    <PMID>30958667</PMID>
  </reference>
  <reference>
    <citation>Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90. doi: 10.1089/AID.2012.0089. Epub 2012 Oct 10.</citation>
    <PMID>22935078</PMID>
  </reference>
  <reference>
    <citation>Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. doi: 10.1128/AAC.01017-16. Print 2016 Nov.</citation>
    <PMID>27572401</PMID>
  </reference>
  <reference>
    <citation>Zheng JH, Guida LA, Rower C, Castillo-Mancilla J, Meditz A, Klein B, Kerr BJ, Langness J, Bushman L, Kiser J, Anderson PL. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal. 2014 Jan;88:144-51. doi: 10.1016/j.jpba.2013.08.033. Epub 2013 Aug 31.</citation>
    <PMID>24055850</PMID>
  </reference>
  <reference>
    <citation>Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011 Feb;66(2):240-50. doi: 10.1093/jac/dkq447. Epub 2010 Nov 30. Review.</citation>
    <PMID>21118913</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Positive</keyword>
  <keyword>Post Renal Transplant</keyword>
  <keyword>Bictegravir/Emtricitabine/Tenofovir Alafenamide</keyword>
  <keyword>Antiretroviral</keyword>
  <keyword>Biktarvy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

